Press Releases

Date Title
Toggle Summary Kura Oncology Announces Data Presentations for Tipifarnib at the International Conference on Malignant Lymphoma and the European Hematology Association Annual Meeting
LA JOLLA, Calif. , June 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that preliminary data from the ongoing Phase 2 clinical trial evaluating the efficacy,
Toggle Summary Kura Oncology to Participate in Two Upcoming Investor Conferences
LA JOLLA, Calif. , May 30, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, is scheduled to
Toggle Summary Kura Oncology Reports First Quarter 2017 Operational and Financial Results
Management to host webcast and conference call today at 4:30 p.m. EDT LA JOLLA, Calif. , May 15, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. , (NASDAQ:KURA) a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today reported first quarter 2017
Toggle Summary Kura Oncology to Report First Quarter 2017 Financial Results
LA JOLLA, Calif. , May 08, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report first quarter 2017 financial results after the close of U.S.
Toggle Summary Kura Oncology Granted U.S. Patent for Clinical-Stage ERK Inhibitor, KO-947
LA JOLLA, Calif. , April 19, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced issuance of a U.S. patent for KO-947, its drug candidate targeting
Toggle Summary Kura Oncology Doses First Patient in Phase 1 Trial of ERK Inhibitor KO-947
LA JOLLA, Calif. , April 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that the first patient has been dosed in its Phase 1 clinical trial of  KO-947, a
Toggle Summary Kura Oncology Presents Preclinical Data Demonstrating Significant Anti-Tumor Activity of KO-947 and KO-539
LA JOLLA, Calif. , April 05, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the presentation of preclinical data for KO-947, its development candidate targeting
Toggle Summary Preclinical Data for Kura Oncology Development Compounds to be Presented at AACR Annual Meeting 2017
LA JOLLA, Calif. , March 29, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines, today announced that results from preclinical studies of tipifarnib, KO-947, its development candidate targeting
Toggle Summary Kura Oncology Reports Fourth Quarter and Full Year 2016 Operational and Financial Results
Management to host webcast and conference call today at 4:30 p.m. EDT LA JOLLA, Calif. , March 14, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. , (NASDAQ:KURA) a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today reported fourth quarter
Toggle Summary Kura Oncology to Report Fourth Quarter and Full Year 2016 Financial Results
LA JOLLA, Calif. , March 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report fourth quarter and full year 2016 financial results after the close